CISI FIN Initiates Coverage on DUALITYBIO-B (09606) with "Overweight" Rating, Highlights Leadership in Next-Gen ADC Innovation

Stock News11-28

CISI FIN released a research report initiating coverage on DUALITYBIO-B (09606) with an "Overweight" rating. The company focuses on the ADC (antibody-drug conjugate) field, leveraging collaborations with global leaders like BioNTech to rapidly advance global multicenter clinical trials, securing a competitive edge.

Key developments include: - **DB-1303** for HER2+ (including high/low expression) endometrial cancer is nearing approval in the U.S. and China. - **DB-1311** shows potential in treating CRPC and other differentiated indications. - Next-gen ADC therapies, including ADC+IO 2.0 combinations, differentiated IO bispecific ADCs, autoimmune ADCs, and novel toxin ADC pipelines, are progressing well, supporting long-term growth.

**Recent Updates**: - On October 23, 2025, DUALITYBIO-B hosted an R&D Day, outlining ADC pipeline progress and future directions. - On November 11, 2025, partner BioNTech showcased clinical plans for DUALITYBIO-B’s ADC candidates combined with PD-L1/VEGF immune antibodies. - On November 14, 2025, the autoimmune ADC **DB-2304 (BDCA2 ADC)** for systemic lupus erythematosus dosed its first patient in the Phase 2a portion of a global 1/2a study. - On November 24, 2025, DB-2304’s single-dose escalation results were presented at AIC 2025, demonstrating strong tolerability and pharmacokinetics. The company will also disclose Phase 1/2a data for **DB-1310 (HER3 ADC)** in HR+/HER2- breast cancer at SABCS 2025.

**Global Clinical Progress**: - **DB-1303 (HER2 ADC)**: U.S. BLA submission for endometrial cancer expected in 2026. A global Phase 3 trial for HR+/HER2-low breast cancer and a China Phase 3 trial for 2L+ HER2+ breast cancer (primary endpoint met in September 2025) are underway, with a China BLA planned by year-end. - **DB-1311 (B7H3 ADC)**: A global Phase 2 basket trial (covering SCLC, CRPC, etc.) is ongoing, with potential in frontline SCLC treatment via combination with PD-L1/VEGF bispecific antibodies.

**Autoimmune ADC Breakthrough**: - **DB-2304 (BDCA2 ADC)** exhibits promising tolerability and pharmacokinetics, positioning it as a potential first-in-class ADC for autoimmune diseases.

**Risks**: Policy changes, intensifying competition, and delays in regulatory approvals.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment